Patients Willing To Pay More For Avoiding Symptoms Of GERD

Published May 17, 2013
Hamilton, ON, Canada - Gastroesophageal reflux disease (GERD) affects about 25% of the population in Western countries. Patients suffer symptoms at least monthly and five percent have daily heartburn. In the study, “Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment,” published in Value in Health, researchers found that patient treatment choices for GERD were most affected by the likelihood of side effects, followed by sleeping discomfort due to GERD, daytime discomfort, dietary changes, medication cost and treatment frequency. The researchers discovered that patients were willing to pay more to reduce susceptibility of GERD side effects from moderate to mild, and to relieve several GERD symptoms. Older patients (over 65) were willing to pay less for daytime discomfort relief than those younger than 65, and women were willing to pay more to avoid sleeping discomfort than men. Lead author, Ken Deal, Ph.D., from McMaster University, states: “This information can guide physicians to select the most appropriate therapy for their individual patients, help to optimize treatment strategies, and improve treatment adherence.”

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×